NCT07217496 2026-03-17
N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer
University of California, San Francisco
Phase 1 Withdrawn
University of California, San Francisco
Rush University Medical Center
Ossium Health, Inc.
M.D. Anderson Cancer Center
University of Florida
M.D. Anderson Cancer Center
The University of Texas Health Science Center, Houston
City of Hope Medical Center